Trial Profile
A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 11 Sep 2018 Results published in the Clinical Cancer Research
- 17 Aug 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 30 Apr 2018 to 28 Jun 2018.